[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639718":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":10,"id":43,"slug":10,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Takotsubo patients with preserved OR mildly reduced\u002Freduced LVEF at acute event.",null,"Takotsubo patients divided in subgroups based on preserved or mildly reduced\u002Freduced LVEF at acute event.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Mark Jovanović, MD","CONTACT","+38640977307","mark.jovanovic@kclj.si",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":20},"Principal Investigator","gregor.poglajen@kclj.si",[22],{"facility":23,"status":24,"city":25,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia","RECRUITING","Ljubljana","1000","Slovenia",{"type":29,"coordinates":30},"Point",[31,32],14.50513,46.05108,{"lat":32,"lon":31},[35],{"name":36,"role":15,"phone":37,"phoneExt":10,"email":38},"Jovanović, Prof. Poglajen","Jovanović: +38640977307","mark.jovanovic@kclj.si ; gregor.poglajen@kclj.si",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Gregor Poglajen","Associate Professor","100639718",false,"NCT07604467","The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome","Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome","STRESS","Inclusion Criteria:\n\n* Minimum age 18 years\n* Established TTS per InterTak registry criteria\n* Signed consent form\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Ischemic heart disease with at least one complete total occlusion\n* Other concurrent cardiomyopathies\n* Active infectious myocarditis\n* obstructive coronary artery disease\n* Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event\n* Previous interventional coronary artery procedure in the last 6 months before TTS acute event\n* Significant valvular heart disease\n* Significant peripheral artery occlusive disease\n* Active or remitted hematologic malignancy\n* Patients receiving immunosuppressive therapy\n* Significant comorbiditeis affecting patients survival (malignancy)\n* Failure to obtain freely given, informed consent form.","ALL","18 Years",{"count":53,"type":54},40,"ESTIMATED","OBSERVATIONAL","The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.",[58,59,60,61,62],"Tako Tsubo Cardiomyopathy","Microvascular Dysfunction","CD34+ Stem Cells","Heart Failure","Cardiac Contractility Recovery",[64,65,66,67,68],"Takotsubo syndrome","CD34+ stem cells","heart failure","microvascular dysfunction","cardiac contractility recovery","2026-05-17",{"date":71,"type":72},"2026-05-22","ACTUAL",{"date":74,"type":72},"2021-09-06",{"date":76,"type":54},"2026-12-31",{"name":5,"class":6},1]